Rare Disease Diagnostics Market
Rare Disease Diagnostics Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Rare Disease Diagnostics Market Size and Growth
The Rare Disease Diagnostics market is witnessing significant growth, driven by advancements in genetic testing and personalized medicine. Valued at approximately $6 billion in 2023, it is projected to expand at a CAGR of over 8% through 2030, reflecting increased demand for accurate, timely diagnostics in underserved patient populations.
Companies Covered
(Covid 19 Impact Covered)
◍ Retrophin
◍ 3billion
◍ 23andMe
◍ QIAGEN
◍ Illumina
◍ PerkinElmer
◍ Strand Life Sciences
The Rare Disease Diagnostics Market features companies like Retrophin, 3billion, 23andMe, QIAGEN, Illumina, PerkinElmer, and Strand Life Sciences, focusing on innovative genetic testing, data analytics, and personalized medicine. Their advancements enhance diagnosis accuracy and accelerate treatment, driving market growth through improved patient outcomes and expanding service offerings.
Sales revenue highlights:
- Illumina: Approximately $3 billion
- QIAGEN: Around $1.6 billion
- PerkinElmer: About $3 billion
- 23andMe: Estimated $200 million
Request Sample Report
Market Segmentation
By Application
◍ Hospital Laboratories
◍ Diagnostic Laboratories
◍ Genetic Testing Laboratories
◍ Cancer Research Laboratories
◍ Others
Request Sample Report
By Product
Hematology
Oncology
Market Growth
Request Sample Report
$ 30.25 Billion
